149 related articles for article (PubMed ID: 20501505)
21. Paralytic ileus associated with capecitabine.
Laudadio L; Biondi E; D'Ostilio N; Cesta A; Di Giandomenico F; Forciniti S; Nuzzo A
Tumori; 2008; 94(5):742-5. PubMed ID: 19112951
[TBL] [Abstract][Full Text] [Related]
22. Capecitabine-induced inflammation of actinic keratosis: case report and literature review.
Stanciu M; Aubut N; Gagné E; Thibeault MM
J Cutan Med Surg; 2012; 16(5):298-9. PubMed ID: 22971302
[No Abstract] [Full Text] [Related]
23. Capecitabine in breast cancer: current status.
Smorenburg CH; Bontenbal M; Verweij J
Clin Breast Cancer; 2001 Jan; 1(4):288-93; discussion 294. PubMed ID: 11899351
[TBL] [Abstract][Full Text] [Related]
24. Capecitabine cardiac toxicity presenting as effort angina: a case report.
Lestuzzi C; Crivellari D; Rigo F; Viel E; Meneguzzo N
J Cardiovasc Med (Hagerstown); 2010 Sep; 11(9):700-3. PubMed ID: 20093950
[TBL] [Abstract][Full Text] [Related]
25. Response to low-dose oral capecitabine monotherapy in an elderly frail patient with metastatic breast carcinoma and impaired renal function: documentation by fluorodeoxyglucose positron emission tomography.
Basu S; Baghel NS
Jpn J Radiol; 2011 May; 29(4):291-2. PubMed ID: 21607846
[No Abstract] [Full Text] [Related]
26. Clinical efficacy of capecitabine as first-line chemotherapy in metastatic breast cancer--how low can you go?
Yap YS; Kendall A; Walsh G; Banerji U; Johnston SR; Smith IE; O'Brien M
Breast; 2007 Aug; 16(4):420-4. PubMed ID: 17379519
[TBL] [Abstract][Full Text] [Related]
27. Efficacy and toxicity of capecitabine-based chemotherapy in patients with metastatic or advanced breast cancer: results from ten randomized trials.
Wang Y; Yang H; Wei JF; Meng L
Curr Med Res Opin; 2012 Dec; 28(12):1911-9. PubMed ID: 23145857
[TBL] [Abstract][Full Text] [Related]
28. Phase II trial of a novel capecitabine dosing schedule in combination with lapatinib for the treatment of patients with HER2-positive metastatic breast cancer.
Gajria D; Gonzalez J; Feigin K; Patil S; Chen C; Theodoulou M; Drullinsky P; D'Andrea G; Lake D; Norton L; Hudis CA; Traina TA
Breast Cancer Res Treat; 2012 Jan; 131(1):111-6. PubMed ID: 21898114
[TBL] [Abstract][Full Text] [Related]
29. [Cardiotoxicity induced by 5-fluorouracil or capecitabine].
Jensen SA; Baeksgaard L; Petersen LN; Reiter L; Sørensen JB
Ugeskr Laeger; 2010 Jan; 172(1):48-51. PubMed ID: 20056096
[TBL] [Abstract][Full Text] [Related]
30. Pharmacokinetic evaluation of capecitabine in breast cancer.
Daniele G; Gallo M; Piccirillo MC; Giordano P; D'Alessio A; Del Giudice A; La Porta ML; Perrone F; Normanno N; De Luca A
Expert Opin Drug Metab Toxicol; 2013 Feb; 9(2):225-35. PubMed ID: 23301520
[TBL] [Abstract][Full Text] [Related]
31. Capecitabine-induced stomatitis: a likely pathogenetic mechanism of oral lichenoid mucositis.
Mignogna MD; Fortuna G; Falleti J; Leuci S
Eur J Clin Pharmacol; 2009 Oct; 65(10):1057-9. PubMed ID: 19521695
[No Abstract] [Full Text] [Related]
32. Pharmacology and therapeutic efficacy of capecitabine: focus on breast and colorectal cancer.
Aprile G; Mazzer M; Moroso S; Puglisi F
Anticancer Drugs; 2009 Apr; 20(4):217-29. PubMed ID: 19247178
[TBL] [Abstract][Full Text] [Related]
33. A retrospective study evaluating a fixed low dose capecitabine monotherapy in women with HER-2 negative metastatic breast cancer.
Ambros T; Zeichner SB; Zaravinos J; Montero AJ; Ahn E; Aruna M; Kronish L; Mahtani RL; Vogel CL
Breast Cancer Res Treat; 2014 Jul; 146(1):7-14. PubMed ID: 24899084
[TBL] [Abstract][Full Text] [Related]
34. Capecitabine and paclitaxel combination chemotherapy for inoperable or recurrent breast cancer: a phase I dose-finding study by the Kinki Breast Cancer Study Group.
Masuda N; Taguchi T; Nakayama T; Shiba E; Watatani M; Kurebayashi J; Takatsuka Y; Sakamoto J; Noguchi S;
Cancer Chemother Pharmacol; 2008 May; 61(6):989-95. PubMed ID: 17641893
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant capecitabine, docetaxel, cyclophosphamide, and epirubicin for early breast cancer: final analysis of the randomized FinXX trial.
Joensuu H; Kellokumpu-Lehtinen PL; Huovinen R; Jukkola-Vuorinen A; Tanner M; Kokko R; Ahlgren J; Auvinen P; Paija O; Helle L; Villman K; Nyandoto P; Nilsson G; Pajunen M; Asola R; Poikonen P; Leinonen M; Kataja V; Bono P; Lindman H
J Clin Oncol; 2012 Jan; 30(1):11-8. PubMed ID: 22105826
[TBL] [Abstract][Full Text] [Related]
36. Phase I and II study of exisulind in combination with capecitabine in patients with metastatic breast cancer.
Pusztai L; Zhen JH; Arun B; Rivera E; Whitehead C; Thompson WJ; Nealy KM; Gibbs A; Symmans WF; Esteva FJ; Booser D; Murray JL; Valero V; Smith TL; Hortobagyi GN
J Clin Oncol; 2003 Sep; 21(18):3454-61. PubMed ID: 12972520
[TBL] [Abstract][Full Text] [Related]
37. A GINECO randomized phase II trial of two capecitabine and weekly paclitaxel schedules in metastatic breast cancer.
Lortholary A; Hardy-Bessard AC; Bachelot T; de Rauglaudre G; Alexandre J; Bourgeois H; Jaubert D; Paraiso D; Largillier R
Breast Cancer Res Treat; 2012 Jan; 131(1):127-35. PubMed ID: 21947680
[TBL] [Abstract][Full Text] [Related]
38. Capecitabine in breast cancer: the issue of cardiotoxicity during fluoropyrimidine treatment.
Molteni LP; Rampinelli I; Cergnul M; Scaglietti U; Paino AM; Noonan DM; Bucci EO; Gottardi O; Albini A
Breast J; 2010; 16 Suppl 1():S45-8. PubMed ID: 21050310
[TBL] [Abstract][Full Text] [Related]
39. Cancer chemotherapy and cardiovascular risks: is capecitabine-induced hypertriglyceridemia a rare adverse effect?
Seminara P; Losanno T; Emiliani A; Manna G
Cardiology; 2010; 116(1):42-4. PubMed ID: 20431291
[TBL] [Abstract][Full Text] [Related]
40. Efficacy and safety of low-dose metronomic chemotherapy with capecitabine in heavily pretreated patients with metastatic breast cancer.
Fedele P; Marino A; Orlando L; Schiavone P; Nacci A; Sponziello F; Rizzo P; Calvani N; Mazzoni E; Cinefra M; Cinieri S
Eur J Cancer; 2012 Jan; 48(1):24-9. PubMed ID: 21775129
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]